Premium
Refractive changes after anti‐ VEGF injections for diabetic macular edema
Author(s) -
Chatziralli I.,
Chatzipantelis A.,
Dimitriou E.,
Mpourouki E.,
Saitakis G.,
Theodossiadis P.
Publication year - 2017
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2017.0f030
Subject(s) - medicine , aflibercept , ranibizumab , ophthalmology , visual acuity , diabetic macular edema , retinal , diabetic retinopathy , diabetes mellitus , bevacizumab , surgery , chemotherapy , endocrinology
Purpose To evaluate refractive changes after anti‐vascular endothelial growth factor (anti‐ VEGF ) injections for the treatment of diabetic macular edema ( DME ). Methods Participants in this retrospective study were 37 patients (37 eyes) with DME , who received intravitreal anti‐ VEGF injections with either ranibizumab or aflibercept. Spherical equivalent refractive power was evaluated before treatment and at least one month after the last injection where no fluid existed. Demographic characteristics, visual acuity, central retinal thickness and the number of injections were recorded and analyzed. Results Changes in visual acuity and central retinal thickness were statistically significant before and after injections. The spherical equivalent refractive power did not differ significantly pre‐ and post‐ injections. Conclusions Intravitreal anti‐ VEGF injections did not seem to affect the refractive power of patients with DME . Therefore, appropriate spectacle correction can be prescribed any time during ongoing treatment with anti‐ VEGF agents.